Tuesday, November 15, 2016
- 9:00AM-11:00AM
-
Abstract Number: 2778
Is There Any Gender Specific Difference in Discriminative Value of Inflammatory Back Pain Criteria?
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III- 9:00AM-11:00AM
-
Abstract Number: 2683
Isolated Anti-La/SS-B Positivity in Patients Diagnosed with Primary Sjogren Syndrome: Analysis of 222 Patients from the Sjogren Big Data Cohort
Sjögren's Syndrome - Poster II: Clinical Science- 9:00AM-11:00AM
-
Abstract Number: 2489
Joint Damage Appears As Severe As Inflammation According to Physician Visual Analog Scales in Patients with Rheumatoid Arthritis Regardless of Disease Severity at 2 Sites, Which May Limit Results of a Treat-to-Target Strategy
Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events- 9:00AM-11:00AM
-
Abstract Number: 2122
KiSS1 Is a Regulator of ADAMTS4 and ADAMTS5 Expression and Is Post-Transcriptionally Regulated By Micro-RNA N105 in Human OA Chondrocytes
Biology and Pathology of Bone and Joint - Poster I- 9:00AM-11:00AM
-
Abstract Number: 2135
Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation
Biology and Pathology of Bone and Joint - Poster I- 9:00AM-11:00AM
-
Abstract Number: 2854
Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis- 9:00AM-11:00AM
-
Abstract Number: 2634
Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III- 9:00AM-11:00AM
-
Abstract Number: 2264
Lack of Obesity-Related Changes in Adipocytes and Inflammatory Cells in the Infrapatellar Fat Pad (IFP): A Different Type of Fat?
Innate Immunity and Rheumatic Disease - Poster II- 9:00AM-11:00AM
-
Abstract Number: 2824
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis- 9:00AM-11:00AM
-
Abstract Number: 2147
Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II- 9:00AM-11:00AM
-
Abstract Number: 2946
Large Scale Genetic Analysis in BehçEt Disease. Identification of Residues Associated in the HLA Class I Region and New Susceptibility Loci
Vasculitis - Poster III: Rarer Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 2965
Late-Onset Relapse in Patients with Systemic Vasculitis
Vasculitis - Poster III: Rarer Vasculitides- 9:00AM-11:00AM
-
Abstract Number: 2182
Levels of Severity of Hip and Knee OA – Validation of Lay Descriptions
Epidemiology and Public Health - Poster III- 9:00AM-11:00AM
-
Abstract Number: 2550
Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients